189 related articles for article (PubMed ID: 23117877)
1. Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate.
Balss J; Pusch S; Beck AC; Herold-Mende C; Krämer A; Thiede C; Buckel W; Langhans CD; Okun JG; von Deimling A
Acta Neuropathol; 2012 Dec; 124(6):883-91. PubMed ID: 23117877
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.
Balss J; Thiede C; Bochtler T; Okun JG; Saadati M; Benner A; Pusch S; Ehninger G; Schaich M; Ho AD; von Deimling A; Krämer A; Heilig CE
Leukemia; 2016 Apr; 30(4):782-8. PubMed ID: 26582645
[TBL] [Abstract][Full Text] [Related]
3. Metabolic syndromes and malignant transformation: where the twain shall meet.
Bhagwat N; Levine RL
Sci Transl Med; 2010 Oct; 2(54):54ps50. PubMed ID: 20962328
[TBL] [Abstract][Full Text] [Related]
4. IDH mutations in glioma and acute myeloid leukemia.
Dang L; Jin S; Su SM
Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities.
Cairns RA; Mak TW
Cancer Discov; 2013 Jul; 3(7):730-41. PubMed ID: 23796461
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency.
Avellaneda Matteo D; Grunseth AJ; Gonzalez ER; Anselmo SL; Kennedy MA; Moman P; Scott DA; Hoang A; Sohl CD
J Biol Chem; 2017 May; 292(19):7971-7983. PubMed ID: 28330869
[TBL] [Abstract][Full Text] [Related]
7. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Gross S; Cairns RA; Minden MD; Driggers EM; Bittinger MA; Jang HG; Sasaki M; Jin S; Schenkein DP; Su SM; Dang L; Fantin VR; Mak TW
J Exp Med; 2010 Feb; 207(2):339-44. PubMed ID: 20142433
[TBL] [Abstract][Full Text] [Related]
8. Quantitative Imaging of D-2-Hydroxyglutarate in Selected Histological Tissue Areas by a Novel Bioluminescence Technique.
Voelxen NF; Walenta S; Proescholdt M; Dettmer K; Pusch S; Mueller-Klieser W
Front Oncol; 2016; 6():46. PubMed ID: 27014623
[TBL] [Abstract][Full Text] [Related]
9. Single-cell profiling of D-2-hydroxyglutarate using surface-immobilized resazurin analogs.
Cheng H; Li Z; Guo Z; Shao S; Mo L; Wei W; Xue M
Biosens Bioelectron; 2021 Oct; 190():113368. PubMed ID: 34098361
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Sells.
Badur MG; Muthusamy T; Parker SJ; Ma S; McBrayer SK; Cordes T; Magana JH; Guan KL; Metallo CM
Cell Rep; 2018 Oct; 25(4):1018-1026.e4. PubMed ID: 30355481
[TBL] [Abstract][Full Text] [Related]
11. Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system.
Linninger A; Hartung GA; Liu BP; Mirkov S; Tangen K; Lukas RV; Unruh D; James CD; Sarkaria JN; Horbinski C
Neuro Oncol; 2018 Aug; 20(9):1197-1206. PubMed ID: 29660019
[TBL] [Abstract][Full Text] [Related]
12. Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants.
Avellaneda Matteo D; Wells GA; Luna LA; Grunseth AJ; Zagnitko O; Scott DA; Hoang A; Luthra A; Swairjo MA; Schiffer JM; Sohl CD
Biochem J; 2018 Oct; 475(20):3221-3238. PubMed ID: 30249606
[TBL] [Abstract][Full Text] [Related]
13. Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.
Rakheja D; Fuda F; Vandergriff T; Boriack R; Medeiros BC; Frankel AE; Chen W
Hum Pathol; 2015 Feb; 46(2):322-6. PubMed ID: 25481493
[TBL] [Abstract][Full Text] [Related]
14. A tale of two subunits: how the neomorphic R132H IDH1 mutation enhances production of αHG.
Pietrak B; Zhao H; Qi H; Quinn C; Gao E; Boyer JG; Concha N; Brown K; Duraiswami C; Wooster R; Sweitzer S; Schwartz B
Biochemistry; 2011 May; 50(21):4804-12. PubMed ID: 21524095
[TBL] [Abstract][Full Text] [Related]
15. Degradation of D-2-hydroxyglutarate in the presence of isocitrate dehydrogenase mutations.
Berger RS; Ellmann L; Reinders J; Kreutz M; Stempfl T; Oefner PJ; Dettmer K
Sci Rep; 2019 May; 9(1):7436. PubMed ID: 31092874
[TBL] [Abstract][Full Text] [Related]
16. Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry.
Longuespée R; Wefers AK; De Vita E; Miller AK; Reuss DE; Wick W; Herold-Mende C; Kriegsmann M; Schirmacher P; von Deimling A; Pusch S
Acta Neuropathol Commun; 2018 Mar; 6(1):21. PubMed ID: 29499756
[TBL] [Abstract][Full Text] [Related]
17. Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
Dang L; Su SM
Annu Rev Biochem; 2017 Jun; 86():305-331. PubMed ID: 28375741
[TBL] [Abstract][Full Text] [Related]
18. Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila.
Reitman ZJ; Sinenko SA; Spana EP; Yan H
Blood; 2015 Jan; 125(2):336-45. PubMed ID: 25398939
[TBL] [Abstract][Full Text] [Related]
19. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas.
Weller M; Wick W; von Deimling A
Glia; 2011 Aug; 59(8):1200-4. PubMed ID: 21294161
[TBL] [Abstract][Full Text] [Related]
20. Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in Wilms tumors.
Rakheja D; Mitui M; Boriack RL; DeBerardinis RJ
Pediatr Blood Cancer; 2011 Mar; 56(3):379-83. PubMed ID: 21225914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
